The cardiovascular, coagulation and haematological effects of Tiger Snake (Notechis scutatus) prothrombin activator and investigation of release of vasoactive substances

Anaesthesia and Intensive Care

Volumn 26, Issue 5, 1998, Pages 536-547

  Tibballs, J ^a,b,c  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b Royal Children's Hospital

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Envenomation: Tiger Snake, Notechis scutatus, prothrombin activator, cardiovascular, coagulation, haematological, vasoactive

Indexed keywords

DEXAMETHASONE; FIBRINOGEN; HEPARIN; HISTAMINE; INDOMETACIN; KETANSERIN; NITRIC OXIDE; ONDANSETRON; PROMETHAZINE; PROTHROMBIN ACTIVATOR; SEROTONIN; SNAKE VENOM; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VASOACTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSISTED VENTILATION; BLOOD CLOTTING; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DOG; DYSKINESIA; ELECTROCARDIOGRAPHY; FIBRINOGEN BLOOD LEVEL; HEART DILATATION; HEART MUSCLE ISCHEMIA; HEART OUTPUT; HEART RIGHT VENTRICLE; HEART STROKE VOLUME; HEART VENTRICLE FAILURE; HEMATOLOGY; HISTOLOGY; HYPOTENSION; INTRACARDIAC THROMBOSIS; LEUKOPENIA; LUNG ARTERY PRESSURE; LUNG EMBOLISM; LUNG VASCULAR RESISTANCE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; THROMBOCYTOPENIA; TRANSESOPHAGEAL ECHOCARDIOGRAPHY;

ANIMALS; BLOOD CELL COUNT; BLOOD COAGULATION; DOGS; ELAPID VENOMS; ELAPIDAE; HEMODYNAMIC PROCESSES; NITRIC OXIDE; PROTHROMBIN; PROTHROMBIN TIME; RESPIRATION, ARTIFICIAL;

EID: 0031730332     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Tibballs J. The cardiovascular, coagulation and haematological effects of tiger snake (Notechis scutatus) venom. Anaesth Intensive Care 1998; 26:529-535.
2. Francis B, John TR, Seebart C, Kaiser II. New toxins from the venom of the common Tiger Snake (Notechis scutatus). Toxicon 1991; 29:85-96.
3. Tans G, Govers-Reimslag JWP, van Rijn JLML, Rosing J. Purification and properties of a prothromhin activator from the venom of Notechis scutatus. J Biol Chem 1985; 260:9366-9370.
4. Marshall LR, Herrmann RP. Australian snake venoms and their in vitro effect on human platelets. Thrombos Res 1989; 54:269-275.
5. Barnes PJ, Henson PM. Platelet-activating factor. In: Crystal RG, West JB, Barnes PJ, Cherniaek NS, Webel ER, eds. The Lung, Scientific Foundations. Raven Press Ltd, New York 1991; 49-59.
6. Piper PJ, Stewart AG. Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor receptor antagonists. Br J Pharmacol 1987; 90:771-783.
7. Stewart AG. Biological properties of platelet-activating factor. In: Cunningham FM ed. Lipid Mediators. Academic Press, London 1994; 221-295.
8. Goldstein RE, Feuerstein GZ, Bradley LM, Stambouly JJ, Laurindo FRM, Davenport NJ. Cardiovascular effects of platelet-activating factor. Lipids 1991; 26:1250-1256.
9. Fry BG. Structure-function properties of venom components from Australian elapids. Centre for Drug Design and Development, University of Queensland, St Lucia, Qld (undated).
10. 2 from the venom of the Australian Tiger Snake (Notechis scutatus). Arch Biochem Biophys 1995; 318:481-488.
11. Camussi G, Aglietta M, Malavasi F et al. The release of platelet-activating factor from human endothelial cells in culture. J Immunol 1983; 131:2397-2403.
12. Chignard M, LeCouedic JP, Vargaftig BB, Benvcniste J. Platelet-activating factor (PAF-acether) secretion from platelets; effect of aggregating agents. Br J Haematol 1980; 46: 455-464.
13. Prescott SM, Zimmerman GA, McIntyre TM. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proc Natl Acad Sci USA 1984; 81: 3534-3538.
14. Ezra D, Laurindo FR, Czaja JF, Snyder F, Goldstein RE, Feuerstein G. Cardiac and coronary consequences of intracoronary platelet activating factor infusion in the domestic pig. Prostaglandins 1987; 34:41-57.
15. Sybertz EJ, Watkins RW, Baum T, Pula K, Rivelli M. Cardiac, coronary and peripheral vascular effects of acetyl glyceryl ether phosphoryl choline in the anaesthetized dog. J Pharmacol Exp Ther 1985; 232:156-162.
16. Delbridge LM, Stewart AG, Goulter CM, Morgan TO, Harris PJ. Platelet-activating factor and WEB-2086 directly modulate rat cardiomyocyte contractility. J Molecular Cellular Cardiol 1994; 26:185-193.
17. Robertson DA, Genovese A, Levi R. Negative inotropic effect of platelet-activating factor on human myocardium: a pharmacological study. J Pharmacol Exp Ther 1987; 243:834-839.
18. da Silva MB, Herion F, Raskinet R, David JL, Gustin P, Lekeux P. Combined effect of WEB 2086 (Paf antagonist) and ketoprofen (Nsaid) on Paf-induced ex vivo platelet aggregation in bovine. Zentralblatt Fur Veterinarmedizin-Reihe A 1997; 44: 65-71.
19. Wilson DV, Eberhart SW, Robinson NE, Rice R, Gray PR. Cardiovascular responses to exogenous platelet-activating factor (PAF) in anaesthetized ponies, and the effects of a PAF antagonist, WEB 2086. Am J Vet Res 1993; 54:274-279.
20. Bills TK, Smith JB, Silver MJ. Selective release of arachidonic acid from the phospholipids of human platelets in response to thrombin. J Clin Invest 1977; 60:1-6.
21. 2. A review. Fed Proc 1987; 46: 133-138.
22. 2 production in dogs. Prostaglandins 1993; 45:221-228.
23. 2 mediates increased pulmonary microvascular permeability after intestinal reperfusion. J Appl Physiol 1997; 82:592-598.
24. 2 activity of guinea pig isolated perfused lungs: Stimulation and inhibition by anti-inflammatory steroids. Br J Pharmacol 1978; 62:79-89.
25. Shams H, Schulz H, Mohr M, et al. Cyclooxygenase inhibition and effects of hypoxia on pulmonary circulation and gas exchange in anesthetized dogs. Resp Physiol 1989; 75:39-49.
26. 2 receptors in the central regulation of the cardiovascular system. Pharmacol Rev 1994; 46:231-243.
27. Linden AS, Desmecht DJ, Amory H, Beduin JM, Lekeux PM. Cardiovascular responses to exogenous serotonin in healthy calves. Am J Vet Res 1996; 57:731-738.
28. Breuer J, Georgaraki A, Sieverding L, Baden W, Apitz J. Increased turnover of serotonin in children with pulmonary hypertension secondary to congenital heart disease. Ped Cardiol 1996; 17:214-219.
29. el-Kashef H. Hyperglycaemia increased the responsiveness of isolated rabbit's pulmonary artery rings to serotonin. Pharmacol 1996; 53:151-159.
30. Feldberg W, Kellaway CH. The circulatory and pulmonary effects of the venom of the Australian copperhead (Denisonia superba). Aust J Exp Biol Med Sci 1937; 15:81-95.
31. Genovese A, Spadaro G. Highlights in cardiovascular effects of histamine and H1-receptor antagonists. Allergy 1997; 52:67-78.
32. Altman DG. Practical statistics for medical research. Chapman & Hall, London 1991.
33. Tibballs J, Hochmann M, Carter B, Osborne A. An appraisal of techniques for administration of gaseous nitric oxide. Anaesth Intensive Care 1993; 23:844-847.
34. Morrison JJ, Pearn JH, Coulter AR. The mass of venom injected by two elapidae: the Taipan (Oxyuranus scutellatus) and the Australian Tiger snake (Notechis scutatus). Toxicon 1982; 20:739-745.
35. Feldberg W, Kellaway CH. Liberation of histamine from the perfused lung by snake venoms. J Physiol 1937; 90:257-279.
36. Whitaker AN, McKay DG. Induction of hypotension in Rhesus monkeys and rabbits by intravenous thrombin infusion. Lab Invest 1969; 20:79-86.
37. Schneider CL, Engstrom RM. Experimental pulmonary arterial occlusion. Acute cor pulmonale simulating "obstetrical shock" of late pregnancy. Am J Obstet Gynec 1954; 68:691-705.
38. Schini VB, Catovsky S, Durante W, Scott-Burden T, Schafer AI, Vanhoutte PM. Thrombin inhibits induction of nitric oxide synthase in vascular smooth muscle cells. Am J Physiol 1993; 264:H611-H616.
39. Radomski MW, Palmer RMJ, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990; 87:5193-5197.
40. Golino P, Cappelli-Bigazzi m, Ambrosio G et al. Endothelium-derived relaxing factor modulates platelet aggregation in an vivo model of recurrent platelet activation. Circ Res 1992; 71: 1447-1456.
41. Freedman JE, Loscalzo J, Barnard MR, Alpert C, Keaney JF, Michelson AD. Nitric oxide released from activated platelets inhibits platelet recruitment. J Clin Invest 1997; 100:350-356.
42. Keh D, Gerlach M, Kurer I, et al. The effects of nitric oxide (NO) on platelet membrane receptor expression during activation with human alpha-thrombin. Blood Coagulation & Fibrinolysis 1996; 7:615-624.
43. Radomski MW, Vallance P, Whitley G, Foxwell N, Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res 1993; 27:1380-1382.
44. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96:60-68.
45. Adams MR, Jessup W, Hailstones D, Celermajer DS. L-argininc reduces human monocyte adhesion to vascular endothelium and endothelial expression of cell adhesion molecules. Circulation 1997; 95:662-668.
46. Hu W, McNicholl IK, Choy PC, Man RY. Partial agonist effect of the platelet-activating receptor antagonists, WEB 2086 and WEB 2170, in the rat perfused heart. Br J Pharmacol 1993; 110: 645-650.